Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients

Launched by PHRAMONGKUTKLAO COLLEGE OF MEDICINE AND HOSPITAL · Dec 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether the drug montelukast can help prevent liver enzyme elevations in adults who have dengue fever. Dengue is a viral infection that can cause serious illness, and doctors want to see if montelukast can help reduce some of the complications associated with it. The trial will also look at how safe montelukast is for patients.

To participate in this study, you must be over 18 years old and have a confirmed dengue infection. You will need to be admitted to the hospital and provide written consent to join. It’s important to note that people with certain conditions, like severe liver problems or those who are pregnant, cannot participate. If you join the study, you’ll be monitored closely for any side effects while taking the medication. The trial is not yet recruiting participants, but it aims to gather important information about treating dengue with montelukast.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient age \>18 years
• • Dengue infection diagnosed by NS1 antigen, or polymerase chain reaction
• • Admitted to the hospital
• • Written informed consent from patient or attending relative able to and willing to give informed consent
• Exclusion Criteria:
• • Other possible cause of fever other than dengue infection
• • Pregnancy
• • Unable to take medication
• • Aminotransferase level above 150 U/l
• • Allergy to paracetamol or tramadol
• • Paracetamol indicated for condition other than dengue infection
• • Critically ill patient who need ICU or invasive ventilation support
• • History of cirrhosis
• • Unable to communicate
• • Other indication of montelukast
• • History of psychiatric illness